The Thoracic and cardiovascular surgeon · 2026
Pulmonary Endarterectomy in Pediatric Patients: Institutional Experience.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Çetinkaya Çagatay, Ermerak Nezih Onur, Eralp Ela Erdem, Akalın Figen, Ak Koray, Tuncer Eylem, Sagir Altug, Yıldızeli Bedrettin
Аннотация
BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is rare in children, and published experience with pulmonary endarterectomy (PEA) is limited.
METHODS: We retrospectively reviewed six patients (<18 years) who underwent seven PEA procedures at our center between December 2011 and September 2025. Clinical characteristics, perioperative findings, hemodynamic outcomes, and follow-up data were analyzed.
RESULTS: Median age was 13 years (range, 2-17), and five patients were female. Five had a history of pulmonary embolism, while one presented with a hydatid cyst. Risk factors for CTEPH were hydrocephalus with ventriculoperitoneal shunt (n = 2), hydatid cyst disease (n = 1), infective endocarditis with left ventricular outflow tract obstruction (n = 1), and chronic kidney disease with prior COVID-19 infection (n = 1). Preoperative mean systolic pulmonary artery pressure (PAP) was 56 ± 23 mm Hg, mean pulmonary artery pressure (mPAP) was 39 ± 15 mm Hg, and mean pulmonary vascular resistance index (PVRi) was 7.51 ± 4.56 U·m2. Most patients were in World Health Organization functional class III or IV. All patients underwent PEA, with concomitant procedures required in most cases. Postoperatively, mPAP decreased to 21 ± 4 mm Hg and mean PVRi to 2.36 ± 1.36 U·m2. Median intensive care unit and hospital stays were 3.5 and 9 days, respectively. There was one in-hospital mortality; all other patients recovered without major complications.
CONCLUSION: PEA is feasible and effective in carefully selected pediatric patients, including those with complex comorbidities. Significant hemodynamic and functional improvements were achieved, supporting the role of PEA as a potentially curative therapy in this rare and challenging group.
METHODS: We retrospectively reviewed six patients (<18 years) who underwent seven PEA procedures at our center between December 2011 and September 2025. Clinical characteristics, perioperative findings, hemodynamic outcomes, and follow-up data were analyzed.
RESULTS: Median age was 13 years (range, 2-17), and five patients were female. Five had a history of pulmonary embolism, while one presented with a hydatid cyst. Risk factors for CTEPH were hydrocephalus with ventriculoperitoneal shunt (n = 2), hydatid cyst disease (n = 1), infective endocarditis with left ventricular outflow tract obstruction (n = 1), and chronic kidney disease with prior COVID-19 infection (n = 1). Preoperative mean systolic pulmonary artery pressure (PAP) was 56 ± 23 mm Hg, mean pulmonary artery pressure (mPAP) was 39 ± 15 mm Hg, and mean pulmonary vascular resistance index (PVRi) was 7.51 ± 4.56 U·m2. Most patients were in World Health Organization functional class III or IV. All patients underwent PEA, with concomitant procedures required in most cases. Postoperatively, mPAP decreased to 21 ± 4 mm Hg and mean PVRi to 2.36 ± 1.36 U·m2. Median intensive care unit and hospital stays were 3.5 and 9 days, respectively. There was one in-hospital mortality; all other patients recovered without major complications.
CONCLUSION: PEA is feasible and effective in carefully selected pediatric patients, including those with complex comorbidities. Significant hemodynamic and functional improvements were achieved, supporting the role of PEA as a potentially curative therapy in this rare and challenging group.